SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMC NEWS

TMCNET eNEWSLETTER SIGNUP

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Intercept Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline
[October 12, 2017]

SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Intercept Pharmaceuticals, Inc. to Contact Brower Piven before the Lead Plaintiff Deadline


The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) ("Intercept" or the "Company") securities during the period between May 31, 2016 and September 20, 2017, inclusive (the "Class Period"). Investors who wish to become proactively involved in the litigation have until November 27, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Intercept securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securties Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that Ocaliva entailed undisclosed safety risks, including death, to patients suffering from primary biliary cirrhosis (PBC).

According to the complaint, following a September 12, 2017 letter warning physicians against overdosing patients with Ocaliva and advising them that the drug has been tied to liver injuries and death among patients from PBC, and a September 21, 2017 safety announcement by the Food and Drug Administration after reports of multiple deaths, the value of Intercept shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Intercept securities purchased on or after May 31, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html. You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.


Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.


[ Back To TMCnet.com's Homepage ]






Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2017 Technology Marketing Corporation. All rights reserved | Privacy Policy